medigraphic.com

2009, Number 6

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2009; 47 (6)

Tigecycline: in Vitro Antimicrobial Activity in Hospitalized Patients in an Infectology Hospital

Barriga-Angulo G, Osorio-Carranza ML, Sánchez-Hernández EA

Language: Spanish
References: 35
Page: 583-590
PDF size: 78.17 Kb.


ABSTRACT

Objective: to evaluate the antimicrobial in vitro tigecycline activity at a infectology hospital.
Methods: the antimicrobial susceptibility percentages and minimum inhibitory concentrations (MIC) were determined from 135 gram-negative and 65 gram-positive organisms obtained from both genders of any age hospitalized patients severely infected by plaque microdilution technique for 20 different antimicrobials.
Results: tigecycline showed a good antimicrobial activity and MIC 50 and 90 fold lower of all antibiotics assessed for isolated microorganisms including methicillin resistant Staphylococcus aureus, penicillin resistant Streptococcus pneumoniae, as well as for microorganisms in the enterobacteriaceae family and Acinetobacter baumanii.
Conclusions: the extensive use of antimicrobial, disinfectants and antiseptics in the hospital setting have developed elevated antimicrobial resistance levels. Tigecycline could be an initial therapeutic alternative against gram-positive and gram-negative including multi-resistant nosocomial pathogens such as Acinetobacter baumanii and meticillin resistant in intra-abdominal, skin and skin structure infections and in the community acquired pneumonia.


REFERENCES

  1. Fish DN, Ohlinger MJ. Antimicrobial resistance: factors and outcomes. Crit Care Clin 2006;22(2): 291-311.

  2. Frimodt-Moller N, Hammerum AM, Bagger-Skjot L, Hessler JH, Brandt CT, Skov RL, et al. Global development of resistance-secondary publication. Dan Med Bull 2007;54(2):160-162.

  3. Quinn JP. Clinical strategies for serious infection: a North American perspective. Diagn Microbiol Infect Dis 1998;31(2):389-395.

  4. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004;64 (1):63-88.

  5. Hoban DJ, Bouchillom SK, Johnson BM, Hohnson JL, Dowzicky MJ. Tigecycline Evaluation and Surveillance (TEST Program) Group. In vitro activity of tigecycline against 6792 gramnegative and grampositive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005;52(3):215-227.

  6. Fritsche TR, Jones RN. Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Sthaphylococcus aureus recovered from nosocomial and community acquired infections. Int J Antimicrob Agents 2004;24(5): 567-571.

  7. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41(10):1373-1406.

  8. Wyeth Pharmaceutics. Tygacil (tigecycline) for injection (package insert). Philadelphia, PA: Wyeth Pharmaceuticals; 2005.

  9. Garrison MW, Nuemiller JJ. In vitro activity of tigecycline against quinolone-resistant Staphylococcus aureus and vancomicycin-resistant enterococci. Int J Antimicrob Agents 2007;29(2):191-196.

  10. Slover CM, Rodvold KA, Danziger LH. Tigecycline: a novel broad-spectrum antimicrobial. Ann Pharmacother 2007;41(6):965-972.

  11. Curcio D, Fernández F. Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective. J Antimicrob Chemoter 2007;60(2):449-450.

  12. Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus, baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect 2007;55(1):49-57.

  13. Garza GE, Bosques PFJ, González GM, Quintanilla VF, Llaca DJ. Actividad antimicrobiana de la tigeciclina contra algunas especies bacterianas grampositivas y gramnegativas de importancia médica. Enferm Infecc Microbiol 2007;27(4):118-126.

  14. Peredo LVMA, Barriga AG. Resistencia microbiana en los hospitales del Centro Médico La Raza. Rev Med IMSS 1982;20(4):401-405.

  15. Giono CS, García PME, Barriga AG. Tipificación piocínica de Pseudomonas aeruginosa aisladas del Hospital General del Centro Médico La Raza. Rev Latinoam Microbiol 1982;24(2):69-76.

  16. Aparicio GO, Giono CS, Barriga AG. Tipificación de cepas de Enterobacter cloacae y Serratia marcescens causantes de un brote intrahospitalario en una sala de prematuros de una unidad de neonatología. Laboratory Acta 1990;2-3;8.

  17. Barriga AG, Castillo TNP, Alarcón ON. Estudio comparativo de la sensibilidad in vitro a aminoglucósidos en 6200 cepas de gérmenes gramnegativos. Rev Mex Patol Clin 1994;41(2): 51-53.

  18. Barriga AG, Castillo TNP, Alarcón ON, Rojas ML, Peredo LVMA. Patrones de susceptibilidad in vitro de organismos aislados en pacientes hospitalizados. Enferm Infecc Microbiol 1997;17(3): 79-82.

  19. Barriga AG, Rojas ML, Peredo LVMA. Actualidades en los patrones de resistencia a los antimicrobianos en un Centro Médico Nacional. Rev Mex Patol Clin 2001;48(2):65-69.

  20. Barriga AG, Alarcón ON. Actividad antimicrobiana de las 8 fluoroquinolonas en infecciones de vías urinarias y tejidos blandos de pacientes atendidos en el CMR del IMSS. Med Int Mex 2004;20 (3):157-164.

  21. Emori TG. III National Nosocomial Infections Surveillance System. Surveillance definitions for intravascular catheter associated infections. Am J Infect Control 1991;19(1):19-25.

  22. Isenberg HP. Clinical microbiology procedures handbook. Second edition. Washington DC: ASM Press; 2004.

  23. Lynne SG. Update of the clinical microbiology procedures handbook. Second edition. Washington, DC: ASM Press; 2007.

  24. Murray PP. Manual of clinical microbiology. Ninth edition. Washington, DC: ASM Press; 2007.

  25. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Seventeenth Informational Supplement 2007 M100-17.

  26. Fajardo VR, González SS, Anaya FVE, Osorio CL, Gómez NMV. Vigilancia de infecciones nosocomiales. Rev Med IMSS 1995;33(6):571-575.

  27. Juárez MIE, Vázquez RA, Games EJ, Sciandra RM, Mercado AJA, Solórzano ST. Costos de infecciones hospitalarias en un grupo de pacientes en un hospital de tercer nivel. Gac Med Mex 1999;135 (5):457-462.

  28. Molina GJD, Garza RA. Vigilancia de infecciones nosocomiales en un hospital de cardiología. Salud Publica Mex 1999;41(Supl 1):S26-S35.

  29. Higuera F, Rangel-Frausto MS, Rosenthal VD, Soto JM, Castañón J, Franco G, et al. Attributable cost and length of stay for patients with central venous catheter associated bloodstream infection in Mexico City intensive care units: a prospective, matched analysis. Infect Control Hosp Epidemiol 2007;28(1):31-35.

  30. Ángeles-Garay U, Velázquez-Chávez Y, Anaya- Flores V, Valencia-Martínez JC, López-Guerrero ME. Infecciones nosocomiales en un hospital de alta especialidad, factores asociados de mortalidad. Rev Med IMSS 2005:43(5):381-389.

  31. Salazar HH, Mireles-Huerta MC, Moreno-Díaz MP, Martínez-Bustamante LE. Infecciones nosocomiales en un hospital de segundo nivel. Rev Med IMSS 2002;40(1):44-51.

  32. Dillman C. Epidemiology of nosocomial infections. 10 month experience in one hospital. Curr Ther Res 1999;57(13):26-29.

  33. Murray CK, Hospenthal DR. Treatment of multidrug resistant acinetobacter. Curr Opin Infect Dis 2005; 18(6):502-506.

  34. Hawkey P, Finch R. Tigecycline: in-vitro performance as a predictor of clinical efficacy. Clin Microbiol Infect 2007;13(4):354-362.

  35. Fomin P, Beuran M, Gradauskas A, Barauskas G, Datsenko A, Dartois N, et al. Tigecycline is efficacious in the treatment of complicated intraabdominal infections. Int J Surg 2005;3(1):35- 47.




2020     |     www.medigraphic.com